The Latest Breaking News from Barchart

vTv Therapeutics (VTVT) is a $156 million biopharma focused on small molecule drugs for Alzheimer’s, diabetes, and inflammatory disorders, all in clinical trials. VTVT has surged 182% over the past year, hitting a two-year high, with strong technical momentum. Wall Street leans “Strong Buy” with targets up to $47, but...

Tesla stock has been flat over the last 2 months. But investors are making money by selling short out-of-the-money (OTM) put options. For example, over the next month, a 6% OTM put provides a 3.2% income yield.

These Dividend Aristocrats have strong earnings growth, solid yields, and Wall Street buy ratings stand out as smart income plays for 2026.

AppLovin shares lost another 8% in the first trading session of 2026, but fundamentals suggest APP stock is worth owning on the pullback.

I look back on the unusual options activity in Q4 2025, highlighting my best and worst bets. One thing I learned about options during the fourth quarter is that sometimes you can be overly clever with your strategy. Don’t be.

Chubb (CB) is trading at new 20-year highs and has strong technical momentum. Shares are up 13% over the past year, making it a slow-and-steady insurance stock. CB maintains a 100% technical “Buy” opinion from Barchart. Analysts and individual investors are largely bullish on the stock with price targets as...

Alphabet, Inc. is set to announce earnings early next month. Whether GOOGL stock rises or stays flat, investors can make a 2.0% income yield by shorting one-month out-of-the-money put options.

Ekso Bionics stock soars as Applied Digital announces plans of spinning off its cloud business. Here’s how you should play EKSO shares heading into 2026.

This gold miner stock's strong fundamentals put it at the top of the list.

I discussed Occidental Petroleum's possible dividend hike next month in my Dec. 23, 2025, Barchart article. I showed that OXY stock could be worth $50. Investors are now piling into January 16, 2026, expiry call options.

Puma Biotechnology (PBYI) relies on one product. It has weak fundamentals and has struggled to grow sales. PBYI stock has surged 91% over the past year, driven by technical momentum and speculative trading spikes. Despite technical “Buy” signals, analyst sentiment is mixed, with most rating PBYI as “Hold” or “Sell.”...